Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208117 · ClinicalTrials.gov registry record · Phase 1
A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00208117: Clinical Trial Phase 1 study, sponsored by New York State Psychiatric Institute.
NCT00208117 is a Phase 1 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00208117, a Phase 1 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the relationship between depressive symptoms and markers of inflammation, two predictors of heart disease.
Interventions
- DRUG Sertraline (Zoloft)
- DRUG Simvastatin (Zocor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Why NCT00208117 stopped before completion
NCT00208117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Sertraline (Zoloft) is the first listed.
NCT00208117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00208117 about?
NCT00208117 is a clinical study titled "A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease". The purpose of this study is to examine the relationship between depressive symptoms and markers of inflammation, two predictors of heart disease.
What is the current status of trial NCT00208117?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2005-04. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00208117?
The interventions under investigation include: Sertraline (Zoloft) (DRUG), Simvastatin (Zocor) (DRUG).
Who is sponsoring clinical trial NCT00208117?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00208117's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia